Matthew Geriak
Impact in
- Clinical Biochemistry top 2%
- Bacterial Identification and Susceptibility Testing
- Infectious Diseases top 5%
- Antimicrobial Resistance in Staphylococcus
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- Bacterial Identification and Susceptibility Testing 6
- Co-authors
- George SakoulasVictor NizetRavina KullarFadi HaddadWarren E. RoseMarcus ZervosKerry L. LaPlanteErlinda R. Ulloa
- Journals
- Clinical Infectious Diseases (3 papers)Open Forum Infectious Diseases (3 papers)Infectious Diseases and Therapy (2 papers)Frontiers in Immunology (2 papers)Medicine (1 paper)
- Partner nations
- United StatesAustralia
In The Last Decade
Matthew Geriak
18 papers receiving 451 citations
Peers
Comparison fields: 5 of 63
- Clinical Biochemistry 169
- Infectious Diseases 342
- Applied Microbiology and Biotechnology 22
- Molecular Medicine 53
- Pharmacology 113
Countries citing papers authored by Matthew Geriak
This map shows the geographic impact of Matthew Geriak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Geriak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Geriak more than expected).
Fields of papers citing papers by Matthew Geriak
This network shows the impact of papers produced by Matthew Geriak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Geriak. The network helps show where Matthew Geriak may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Matthew Geriak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 8 | |
| 5 | 2022 | 8 | |
| 6 | 2022 | 6 | |
| 7 | 2022 | 3 | |
| 8 | 2021 | 22 | |
| 9 | 2021 | 46 | |
| 10 | 2021 | 10 | |
| 11 | 2020 | 22 | |
| 12 | Multicenter Cohort of Patients With Methicillin-Resistant | 2020 | 1 |
| 13 | 2020 | 35 | |
| 14 | 2019 | 65 | |
| 15 | 2019 | 138 | |
| 16 | 2019 | 33 | |
| 17 | 2018 | 30 | |
| 18 | 2014 | 23 | |
| 19 | 2009 | 4 |
About Matthew Geriak
Matthew Geriak is a scholar working on Applied Microbiology and Biotechnology, Clinical Biochemistry, Infectious Diseases, Pharmacology and Geriatrics and Gerontology, having authored 19 papers that have together received 456 indexed citations. Recurring topics across this work include Antimicrobial Resistance in Staphylococcus (9 papers), Bacterial Identification and Susceptibility Testing (6 papers), COVID-19 Clinical Research Studies (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers), Infective Endocarditis Diagnosis and Management (3 papers), Urinary Tract Infections Management (2 papers), Drug-Induced Adverse Reactions (2 papers) and Clostridium difficile and Clostridium perfringens research (2 papers). The work is most often cited by research in Clinical Biochemistry (169 citations), Infectious Diseases (342 citations), Applied Microbiology and Biotechnology (22 citations), Molecular Medicine (53 citations) and Pharmacology (113 citations). Matthew Geriak has collaborated with scholars based in United States and Australia. Frequent co-authors include George Sakoulas, Victor Nizet, Ravina Kullar, Fadi Haddad, Warren E. Rose, Marcus Zervos, Kerry L. LaPlante, Erlinda R. Ulloa, Lucas Schulz and Michael J. Rybak. Their work appears in journals such as Clinical Infectious Diseases, Open Forum Infectious Diseases, Infectious Diseases and Therapy, Frontiers in Immunology and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.